Be Biopharma, Inc.

Based in the US, Be Biopharma, Inc. specializes in pioneering engineered B cell medicines, focusing on advanced protein-based therapies designed to address serious diseases such as hemophilia B. Founded in 2020, Be Biopharma, Inc. is located in Cambridge, US.

The company focuses on developing innovative therapies for hemophilia B, enabling enhanced blood-clotting factor production. The firm has completed a total of 4 deals, with its most recent funding round being a Series C on January 15, 2025, which raised USD 92. 00 mn. The funding was led by Nextech, with participation from ARCH Venture Partners, Alta Partners, Atlas Venture, Bristol-Myers Squibb Company, Longwood Fund, RA Capital, and Takeda Ventures.

Be Biopharma was co-founded by Lea Hachigian and Rich James, with Joanne Smith-Farrell serving as CEO. Be Biopharma specializes in the development and commercialization of engineered B cell medicines, focusing on innovative protein-based therapies aimed at addressing serious diseases such as hemophilia B. The company's core offerings leverage advanced scientific strategies to create therapies that enhance the body's ability to produce necessary blood-clotting factors, transforming the treatment landscape for patients. These therapies are designed to provide greater freedom and improved health outcomes for individuals living with hemophilia B, significantly impacting their quality of life.

Be Biopharma serves healthcare providers, patients, and caregivers across North America and Europe, where demand for advanced treatment options in rare diseases is growing. Be Biopharma's revenue structure is based on partnerships and collaborations with healthcare institutions and research organizations. Transactions typically occur through direct engagements with healthcare providers and specialty pharmacies, facilitating the distribution of their proprietary therapies. The company utilizes subscription models or negotiated pricing agreements to ensure access to its flagship therapies, which are essential for managing hemophilia B.

These models foster ongoing relationships with clients, ensuring consistent supply and support for end users, with pricing details and transaction terms reflecting the value of their innovations. In January 2025, Be Biopharma, Inc. raised USD 92. 00 mn in Series C funding, which will be allocated to enhance the clinical treatment of hypophosphatasia.

The company plans to design and launch new products targeting this condition, while also expanding its market presence into additional regions. Specific geographic areas targeted for growth include new territories within North America and Europe by the end of 2025. The recent funding will support these strategic initiatives, aiming to improve patient access to groundbreaking therapies.